Home » Stocks » BWAY

Brainsway Ltd. (BWAY)

Stock Price: $7.86 USD -0.23 (-2.80%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
After-hours: $7.85 -0.01 (-0.13%) Jan 19, 4:41 PM
Market Cap 93.55M
Revenue (ttm) 23.10M
Net Income (ttm) -10.33M
Shares Out 21.64M
EPS (ttm) -0.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $7.86
Previous Close $8.09
Change ($) -0.23
Change (%) -2.80%
Day's Open 7.82
Day's Range 7.80 - 7.95
Day's Volume 13,846
52-Week Range 5.23 - 12.31

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 3 weeks ago

FDA clearance for smoking cessation moves Brainsway towards a portfolio of neurological disorder treatments and extends the company's competitive advantage. The publication of positive real-wo...

Seeking Alpha - 2 months ago

Brainsway Ltd. (BWAY) CEO Chris von Jako on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Monday, November 23, 2020, at 10:00 AM Eastern Time Monday, November 23, 2020, at 10:00 AM Eastern Time

GlobeNewsWire - 2 months ago

CRESSKILL, N.J. and JERUSALEM, Nov. 04, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of b...

GlobeNewsWire - 3 months ago

In conjunction with OCD Awareness Week, BrainsWay partners with mental health influencers and patients to increase education around misrepresentation of the disorder In conjunction with OCD Aw...

GlobeNewsWire - 3 months ago

Deep TMS highlighted in 10 presentation posters at annual session Deep TMS highlighted in 10 presentation posters at annual session

GlobeNewsWire - 4 months ago

CRESSKILL, N.J. and JERUSALEM, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive tr...

Zacks Investment Research - 4 months ago

As of late, it has definitely been a great time to be an investor in Brainsway.

GlobeNewsWire - 4 months ago

CRESSKILL, N.J. and JERUSALEM, Sept. 02, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment ...

Zacks Investment Research - 4 months ago

Brainsway (BWAY) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Seeking Alpha - 4 months ago

Brainsway’s current valuation is low as a result of a decline in revenue due to COVID-19 lockdowns.s

InvestorPlace - 4 months ago

Brainsway (BWAY) news for Monday includes approval from the U.S. Food & Drug Administration (FDA) sending BWAY stock higher.

GlobeNewsWire - 4 months ago

Company Intends to Execute a Controlled U.S. Market Release in Early 2021

Seeking Alpha - 5 months ago

BrainsWay Ltd. (BWAY) CEO Christopher von Jako on Q2 2020 Results - Earnings Call Transcript

Benzinga - 5 months ago

Shares of Brainsway (NASDAQ:BWAY) remained unaffected after the company reported Q2 results.

GlobeNewsWire - 5 months ago

CRESSKILL, N.J. and JERUSALEM, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive tre...

GlobeNewsWire - 5 months ago

CRESSKILL, N.J. and JERUSALEM, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive trea...

GlobeNewsWire - 5 months ago

PATTERSON, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disor...

Seeking Alpha - 6 months ago

BrainsWay Ltd. (BWAY) CEO Christopher von Jako on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

PATTERSON, N.J. and JERUSALEM, June 24, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today, June 24th, by BrainsWay Ltd. (NASDAQ & TASE: BWAY), please note th...

GlobeNewsWire - 6 months ago

PATTERSON, N.J. and JERUSALEM, June 24, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment o...

GlobeNewsWire - 7 months ago

New site features user-friendly layout, easy access to resources, and tools for those affected by COVID-19 New site features user-friendly layout, easy access to resources, and tools for those...

GlobeNewsWire - 7 months ago

PATTERSON, N.J., May 20, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorde...

GlobeNewsWire - 8 months ago

Hadar Levy Promoted to Senior Vice President and General Manager of North America

GlobeNewsWire - 8 months ago

BrainsWay will donate $1 per entry to the National Alliance of Mental Illness (NAMI) and each entry will be entered for a chance to win a $250 Amazon gift card BrainsWay will donate $1 per ent...

GlobeNewsWire - 9 months ago

PATTERSON, N.J., April 13, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disor...

Seeking Alpha - 9 months ago

Brainsway Continues Growth Trajectory While Conserving Cash

Seeking Alpha - 9 months ago

Brainsway Ltd. (BWAY) CEO Christopher von Jako on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 11 months ago

Results demonstrate increased activity in attention-related brain networks treated with BrainsWay’s H6-coil, which correlate with observed improvement in ADHD symptoms

GlobeNewsWire - 11 months ago

Lushi also to serve on Company’s audit committee Lushi also to serve on Company’s audit committee

GlobeNewsWire - 11 months ago

Company to discontinue funding of study following insufficient demonstration of efficacy Company to discontinue funding of study following insufficient demonstration of efficacy

Market Watch - 1 year ago

Shares of Brainsway are up 10% in premarket trading on positive trial results for its brain stimulation device as a smoking cessation tool for longtime chronic cigarette smokers.

GlobeNewsWire - 1 year ago

Primary and secondary endpoint achieved with statistical significance

Seeking Alpha - 1 year ago

Brainsway Ltd. (BWAY) CEO David Zacut on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

JERUSALEM and HACKENSACK, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) and its subsidiary BrainsWay USA, Inc., a global leader in the advanced non-invasive tr...

GlobeNewsWire - 1 year ago

JERUSALEM, Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in the advanced non-invasive treatment of brain disorders, announced today that it wil...

GlobeNewsWire - 1 year ago

Deep Transcranial Magnetic Stimulation (Deep TMS) helmet approved to treat MDD is now available in Greenwood Village Deep Transcranial Magnetic Stimulation (Deep TMS) helmet approved to treat ...

Seeking Alpha - 1 year ago

BrainsWay is a technology leader in the transcranial magnetic stimulation market which holds significant potential if it becomes widely accepted by doctors and patients.

About BWAY

Brainsway, a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to tra... [Read more...]

Industry
Diagnostics & Research
IPO Date
Apr 17, 2019
Stock Exchange
NASDAQ
Ticker Symbol
BWAY
Full Company Profile

Financial Performance

In 2019, Brainsway's revenue was $23.10 million, an increase of 40.89% compared to the previous year's $16.40 million. Losses were -$10.33 million, 59.4% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Brainsway stock is "Strong Buy." The 12-month stock price forecast is 11.19, which is an increase of 42.37% from the latest price.

Price Target
$11.19
(42.37% upside)
Analyst Consensus: Strong Buy